Adagrasib is the second-most selective KRAS inhibitor currently being reviewed by the FDA for accelerated approval for patients with lung cancer who harbor the KRAS c.34G > T (p.G12C) mutation. This evidence concerns the gene KRAS and lung carcinoma.